Loading...
XJPX4531
Market cap36mUSD
Jan 09, Last price  
267.00JPY
1D
-1.11%
1Q
-0.74%
Jan 2017
5.12%
Name

Yuki Gosei Kogyo Co Ltd

Chart & Performance

D1W1MN
XJPX:4531 chart
P/E
7.44
P/S
0.45
EPS
35.87
Div Yield, %
2.63%
Shrs. gr., 5y
—
Rev. gr., 5y
4.71%
Revenues
12.93b
+0.72%
10,501,403,00010,411,013,0009,602,831,0009,322,316,0008,116,579,0008,609,017,0009,422,580,00010,005,178,00010,576,448,00010,396,051,00010,073,000,00010,272,000,00010,717,000,00011,091,000,00012,361,000,00012,839,000,00012,932,000,000
Net income
776m
+39.57%
261,646,000-782,875,000-567,622,000-11,963,000207,735,000337,890,00053,504,000330,209,000350,746,000355,307,000125,000,000104,000,000-42,000,000288,000,000248,000,000556,000,000776,000,000
CFO
388m
-41.92%
1,543,069,000956,097,000144,956,0001,996,218,000-386,449,0001,197,487,0001,769,209,0001,384,604,000590,572,000486,083,000687,000,000656,000,0001,420,000,000352,000,0001,787,000,000668,000,000388,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Jan 29, 2025

Profile

Yuki Gosei Kogyo Co., Ltd. researches, develops, manufactures, and markets fine chemical products in Japan and internationally. It offers food additives, pharmaceuticals, and industrial and agricultural chemicals; and glycine, glycine compounds, nicotinic acid amide, isoniazid, drug intermediates, and cosmetic ingredients. The company also provides amino acid, pyridine, piperidine, silicon, and other compounds; DNA, nucleoside, and protamine; and active pharmaceutical ingredients. In addition, it engages in the contract manufacturing of pharmaceuticals and chemical products. Yuki Gosei Kogyo Co., Ltd. was founded in 1947 and is headquartered in Tokyo, Japan.
URL
https://www.yuki-gosei.co.jp/
IPO date
Oct 02, 1962
Employees
295
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
12,932,000
0.72%
12,839,000
3.87%
12,361,000
11.45%
Cost of revenue
11,736,000
10,676,000
10,807,000
Unusual Expense (Income)
NOPBT
1,196,000
2,163,000
1,554,000
NOPBT Margin
9.25%
16.85%
12.57%
Operating Taxes
129,000
84,000
41,000
Tax Rate
10.79%
3.88%
2.64%
NOPAT
1,067,000
2,079,000
1,513,000
Net income
776,000
39.57%
556,000
124.19%
248,000
-13.89%
Dividends
(152,000)
(87,000)
(65,000)
Dividend yield
2.20%
1.34%
1.09%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
4,629,000
4,436,000
4,014,000
Long-term debt
2,594,000
1,584,000
1,889,000
Deferred revenue
373,000
1,087,000
1,113,000
Other long-term liabilities
1,486,000
6,000
6,000
Net debt
4,510,000
3,123,000
2,242,000
Cash flow
Cash from operating activities
388,000
668,000
1,787,000
CAPEX
(1,834,000)
(1,158,000)
(383,000)
Cash from investing activities
(1,894,000)
(1,237,000)
(442,000)
Cash from financing activities
948,000
(158,000)
(772,000)
FCF
(1,662,000)
818,000
2,564,000
Balance
Cash
588,000
1,143,000
1,856,000
Long term investments
2,125,000
1,754,000
1,805,000
Excess cash
2,066,400
2,255,050
3,042,950
Stockholders' equity
6,009,000
8,597,000
8,122,000
Invested Capital
18,344,600
15,791,950
14,524,050
ROIC
6.25%
13.72%
10.10%
ROCE
5.69%
11.60%
8.55%
EV
Common stock shares outstanding
21,824
21,824
21,825
Price
317.00
6.73%
297.00
8.39%
274.00
-11.04%
Market cap
6,918,080
6.73%
6,481,857
8.39%
5,980,125
-11.04%
EV
11,428,080
9,604,857
8,222,125
EBITDA
2,125,000
3,091,000
2,451,000
EV/EBITDA
5.38
3.11
3.35
Interest
49,000
50,000
50,000
Interest/NOPBT
4.10%
2.31%
3.22%